PressAugust 4, 2020 Mindleap Health™ Expands its Digital Mental Health Programs for Addiction, Psychedelic Integration and Holistic Wellness
PressAugust 3, 2020 Usona Institute Publishes Breakthrough Development in Scalable Psilocybin Synthesis
PressJuly 31, 2020 Revive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19
PressJuly 30, 2020 Novamind Closes the Acquisition of Cedar Psychiatry, a Leading Psychedelic Therapy Organization in the U.S.
PressJuly 30, 2020 Numinus and Together We Can Partner to Support Addiction Recovery and Mental Wellness
PressJuly 29, 2020 Cybin Corp. to Deliver Psychedelic Medicines Targeting Conditions Failed by Big Pharma
PressJuly 29, 2020 Numinus Announces Short Form Prospectus Offering of Units for Gross Proceeds of up to $4,050,000
PressJuly 24, 2020 MOTA Ventures Announces European Expansion Through Joint Venture Agreement With Franchise Cannabis
PressJuly 23, 2020 ATAI launches Viridia Life Sciences to develop novel formulations of N, N-Dimethyltryptamine (DMT) for a range of mental health conditions
PressJuly 21, 2020 The Lundquist Institute Accepts a $1.75 Million Anonymous Donation to Improve the Quality of Dying
PressJuly 21, 2020 Mindleap Health Signs Agreement with Brightmind to Launch Comprehensive Meditation Program
PressJuly 21, 2020 Cybin Corp. Announces Proposed Management Team and Board of Directors of the Resulting Issuer
PressJuly 17, 2020 Wuhan General Group Signs MOA for the Acquisition of Tsime Pharmaceuticals (PTY) Limited
